Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis
Therapeutic Advances in Hematology
Published online on January 03, 2026
Abstract
Therapeutic Advances in Hematology, Volume 17, January-December 2026.
Background:Individuals diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL) typically exhibit a dismal prognosis when treated with conventional therapeutic modalities. CD19—targeted chimeric antigen receptor T (CAR-T) cell therapy has ...
Background:Individuals diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL) typically exhibit a dismal prognosis when treated with conventional therapeutic modalities. CD19—targeted chimeric antigen receptor T (CAR-T) cell therapy has ...